Sulthiame

Highest phase reached
Approved
www.ebi.ac.uk
Drug type
Small molecule
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Approved
www.ebi.ac.uk

Drug type
Small molecule
www.ebi.ac.uk
Drug name
Sulthiame
www.ebi.ac.uk
Molecular weight
290.37
www.ebi.ac.uk
Structure (SMILES)
NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1
www.ebi.ac.uk

  • conadil
  • Conadil
  • ospolot
  • Ospolot
  • trolone
  • Trolone

  • 4 tetrahydro 2h 1 2 thiazin 2 yl benzenesulfonamide s s dioxide
  • 4-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide, S,S-dioxide
  • benzenesulfonamide 4 tetrahydro 2h 1 2 thiazin 2 yl s s dioxide
  • BENZENESULFONAMIDE, 4-(TETRAHYDRO-2H-1,2-THIAZIN-2-YL)-, S,S-DIOXIDE
  • ospolot 200 mg
  • p tetrahydro 2h 1 2 thiazin 2 yl benzenesulfonamide s s dioxide
  • P-(TETRAHYDRO-2H-1,2-THIAZIN-2-YL)BENZENESULFONAMIDE, S,S-DIOXIDE
  • riker 594
  • RIKER 594
  • RIKER-594
  • sulthiame
  • Sulthiame
  • SULTHIAME [MI]
  • SULTHIAME [USAN]
  • sulthiame mi
  • sulthiame usan
  • sultiame
  • Sultiame
  • sultiame [INN]
  • SULTIAME [JAN]
  • SULTIAME [MART.]
  • Sultiame [WHO-DD]
  • sultiame inn
  • sultiame jan
  • sultiame mart

And 3 more, listed on the interactive page.

ATC classification codes
  • N03AX03
Sources for recorded values
www.ebi.ac.uk
CAS registry numbers
  • 61-56-3
ChEMBL ID
CHEMBL328560
www.ebi.ac.uk
InChIKey
HMHVCUVYZFYAJI-UHFFFAOYSA-N
www.ebi.ac.uk
PubChem compound IDs
  • 5356
RxNorm IDs (RxCUI)
  • 10240
FDA ingredient codes (UNII)
  • I00Q766CZ2

Patents
0
Designations
1
First in class
No
Fast track
No
Breakthrough designation
No
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No

  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    O43570
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P00915
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P00918
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P07451
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P22748
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P23280
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P35218
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    P43166
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    Q16790
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    Q8N1Q1
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    Q9ULX7
  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase
    Protein identifier
    Q9Y2D0

Open Targets mechanisms

  • Mechanism
    Carbonic anhydrase inhibitor
    Action type
    Inhibitor
    Target
    Carbonic anhydrase

  • Condition
    Epilepsy
    Highest recorded phase
    4
    Condition identifier
    EFO:0000474
    Subject identifier
    D004827
  • Condition
    Sleep Apnea, Obstructive
    Highest recorded phase
    2
    Condition identifier
    EFO:0003918
    Subject identifier
    D020181

  • Condition identifier
    EFO_0000474
  • Condition identifier
    EFO_0003918
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005027
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0007147
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0020072

  • Event
    aggression
    Reports
    8
    Reporting signal score
    19.5063
  • Event
    ataxia
    Reports
    4
    Reporting signal score
    10.5051
  • Event
    attention deficit/hyperactivity disorder
    Reports
    3
    Reporting signal score
    12.1453
  • Event
    bronchitis
    Reports
    6
    Reporting signal score
    11.009
  • Event
    congenital cyst
    Reports
    14
    Reporting signal score
    124.098
  • Event
    disturbance in attention
    Reports
    9
    Reporting signal score
    25.176
  • Event
    drug interaction
    Reports
    8
    Reporting signal score
    8.62905
  • Event
    drug intolerance
    Reports
    7
    Reporting signal score
    10.7197
  • Event
    electroencephalogram abnormal
    Reports
    5
    Reporting signal score
    21.6514
  • Event
    epilepsy
    Reports
    20
    Reporting signal score
    73.6248
  • Event
    low birth weight baby
    Reports
    10
    Reporting signal score
    41.3137
  • Event
    maternal exposure timing unspecified
    Reports
    3
    Reporting signal score
    12.515
  • Event
    oppositional defiant disorder
    Reports
    2
    Reporting signal score
    11.6423
  • Event
    optic atrophy
    Reports
    2
    Reporting signal score
    8.15419
  • Event
    pectus excavatum
    Reports
    2
    Reporting signal score
    12.8864
  • Event
    seizure
    Reports
    6
    Reporting signal score
    9.11345
  • Event
    small for dates baby
    Reports
    15
    Reporting signal score
    72.7988
  • Event
    therapeutic product effective for unapproved indication
    Reports
    2
    Reporting signal score
    13.1447
  • Event
    therapeutic product ineffective for unapproved indication
    Reports
    2
    Reporting signal score
    11.9395
  • Event
    tonic convulsion
    Reports
    3
    Reporting signal score
    13.8613

Hydrogen bond acceptors
4
Hydrogen bond donors
1
Polar surface area
97.54
Calculated partition coefficient (ALogP)
0.26
Calculated partition coefficient (XLogP)
0.1
Prodrug
No
Chirality
Achiral
Inorganic
No
Rule-of-five violations
0
Rotatable bonds
2
Heavy atoms
18
Molecular formula
C10H14N2O4S2
Monoisotopic mass
290.03949928
Natural product
Yes

Recorded assays
645
Active assays
147

  • Confirmatory
  • Other

Related records

Trials (4)

Approved for (1)

In development for (1)

Targets (12)